T20K Peptide Shows Promise in MS Preclinical Studies & Managing Challenges With MS

Jan 26, 12:00 AM

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how new preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS).
Price also reads the column by Jamie Hughes, A Life in Letters, “When Is a Wall Not Just a Wall?”.
Are you interested in learning more about multiple sclerosis? If so, please visit:
To join in on conversations regarding multiple sclerosis, please visit: